In a patient allergic to penicillins and cephalosporins with a urine culture growing Proteus mirabilis and Pseudomonas aeruginosa, and given the susceptibility profile (Proteus mirabilis susceptible to ampicillin, ampicillin/sulbactam, cefepime, ceftazidime, ceftriaxone, ciprofloxacin, gentamicin, levofloxacin, meropenem, piperacillin/tazobactam, and trimethoprim‑sulfamethoxazole; intermediate to cefazolin; resistant to nitrofurantoin; Pseudomonas aeruginosa resistant to ciprofloxacin, levofloxacin, and meropenem; intermediate to cefepime; susceptible to aztreonam, amikacin, ceftazidime, piperacillin/tazobactam, and tobramycin), what definitive antimicrobial regimen should be used?

Recommended Antimicrobial Regimen

Use aztreonam as monotherapy for this polymicrobial urinary tract infection, as it is the only non-beta-lactam agent with activity against both Proteus mirabilis and Pseudomonas aeruginosa given your patient's penicillin and cephalosporin allergies.

Rationale for Aztreonam Selection

Given the reported allergies to both penicillins and cephalosporins, your antibiotic options are significantly constrained. The 2023 Dutch Working Party on Antibiotic Policy (SWAB) guidelines provide clear direction: aztreonam can be used in patients with suspected immediate-type allergy to cephalosporins other than ceftazidime or cefiderocol, irrespective of severity and time since the index reaction 1. This is a strong recommendation with low quality of evidence.

Why Aztreonam Works Here

• Proteus mirabilis coverage: While your susceptibility panel doesn't specifically list aztreonam, Proteus mirabilis is generally susceptible to aztreonam, and your isolate shows susceptibility to multiple beta-lactams including ceftazidime (which shares structural similarity with aztreonam)
• Pseudomonas aeruginosa coverage: Your susceptibility testing explicitly confirms the Pseudomonas is susceptible to aztreonam
• Cross-reactivity profile: Aztreonam does not cross-react with other beta-lactams except ceftazidime, with which it shares a common R-group side chain 2. Since you have cephalosporin allergy (not specifically ceftazidime allergy documented), aztreonam remains safe 1

Alternative Options (If Aztreonam Unavailable or Contraindicated)

Aminoglycoside Monotherapy

If aztreonam is not available, gentamicin or tobramycin would be your next choice:

• Both organisms show susceptibility (Proteus to gentamicin; Pseudomonas to tobramycin and amikacin)
• The 2023 ESCMID guidelines conditionally recommend aminoglycosides for short treatments in non-severe UTIs 3
• Critical caveat: Avoid in renal dysfunction or when combined with other nephrotoxic drugs 3
• Aminoglycosides have unclear prostate penetration with conflicting efficacy data 3

Fluoroquinolone Consideration (With Major Limitations)

Do NOT use fluoroquinolones in this case because:

• Your Pseudomonas is resistant to both ciprofloxacin and levofloxacin
• While Proteus is susceptible to fluoroquinolones, treating only one organism in a polymicrobial infection is inadequate

Why Other Options Are Excluded

TMP-SMX: Only covers Proteus mirabilis (susceptible), but has no reliable Pseudomonas coverage. The FDA label confirms Pseudomonas aeruginosa is typically not in the susceptibility spectrum 4.

Ceftazidime: Despite excellent coverage for both organisms on your susceptibility panel, it is contraindicated due to the cephalosporin allergy. The SWAB guidelines specifically warn to avoid aztreonam in patients with suspected immediate-type ceftazidime allergy 1, suggesting cross-reactivity concerns.

Carbapenems: Your Pseudomonas is resistant to meropenem, eliminating this class. Additionally, carbapenems should be considered cross-reactive with penicillin 2, though the 2023 SWAB guidelines suggest carbapenems can be used in a clinical setting for patients with cephalosporin allergy 1.

Treatment Duration and Monitoring

• Duration: 7-14 days depending on clinical response and whether this is complicated UTI 5
• Monitoring: Ensure clinical improvement within 48-72 hours; if no response, consider allergy evaluation to potentially expand antibiotic options
• Follow-up culture: Recommended to document microbiological clearance given polymicrobial infection

Critical Clinical Pitfalls

1. Do not attempt combination therapy with agents that only cover one organism—you need single-agent activity against both pathogens
2. Verify the nature of the reported allergies: Many reported beta-lactam allergies are not true IgE-mediated reactions. If time permits and clinical severity allows, consider allergy testing to potentially expand options 2
3. Assess for complicated UTI features: Obstruction, foreign body, or anatomic abnormalities require source control in addition to antibiotics 5
4. Renal function assessment: Critical for aminoglycoside dosing if used as alternative 3